feed,title,long_url,short_url
MarketWatch,BridgeBio stock plunges after its acoramidis fails to meet primary endpoint in Phase 3 ATTRibute-CM study,http://www.marketwatch.com/news/story/bridgebio-stock-plunges-after-its/story.aspx?guid=%7BAD2741C7%2DC304%2D49D1%2D9233%2D1F182BA804EF%7D&siteid=rss,https://on.mktw.net/3Hgm7eM
